

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**STA Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies**

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation), and, if so, what are they?

Stakeholders commented that patients may not have equal access to treatment geographically if there are limited treatment centres available.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Access to treatment is an implementation issue and cannot be addressed in technology appraisal guidance.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes to the scope are needed.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No changes to the stakeholder list are needed.

Technology Appraisals: Scoping

Equality impact assessment for the single technology appraisal of idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies

Issue date: October 2020

**Approved by Associate Director (name):** .....Ross Dent.....

**Date:** 16 September 2020

Technology Appraisals: Scoping

Equality impact assessment for the single technology appraisal of idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies

Issue date: October 2020